Home
overview

SMi are proud to present their 4th annual COPD: Novel Therapeutics and Management Strategies conference convening in Central London on Monday 22nd and Tuesday 23rd 2012. Consisting of an industry led programme with academic keynote presentations, this event will be the perfect opportunity to hear presentations on the latest hot topics surrounding COPD and to network with key industry professionals. This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.

SMi's 4th annual conference on COPD will provide attendees with a complete view of the field and will focus on novel combination therapies, the latest insights in drug developments and clinical trial design, as well as discussing health economics of COPD drugs. This informative event will bring together key opinion leaders in the field to provide attendees with an in-depth look into current advances in COPD. This year's agenda will provide an unparalleled opportunity for debate and problem solving of key challenges currently facing the field, allowing attendees to discuss progress in the area and exchange ideas moving forward, ensuring a truly comprehensive treatment of the most important issues.

This market-leading event will bring together senior representatives from all over the respiratory community to share knowledge and discuss the latest developments in the field. Testimonials from our successful 2011 event:

'One of the best respiratory conferences I've been to' - Novartis

'Excellent discussions' - Almirall

'Excellent content - interesting discussions' Boehringer-Ingelheim

Consider developments in the modelling and management of exacerbations of COPD

Evaluate unique complexities of COPD pathophysiology - compare and contrast COPD with Asthma to improve your understanding of what makes COPD unique and needing of particular attention

Develop combination and oxygen therapies within COPD - learn about triple therapies and novel therapies within the treatment of COPD

Hear from leading industry professionals on the current clinical trials process and rapid proof of concept.

Analyse all phases of the discovery process, from pre-clinical modelling, phase 2 studies all the way through to modelling clinical outcomes.

Network with and learn from key industry professional and research leading academics

Discuss the latest in health economics for COPD drugs

SMi's 4th annual COPD Conference will build on the success of our previous events and bring together a unique mix of senior executives from the industry, academia and the public sector and will provide an unrivalled forum for problem-solving discussion and debate. This event is unmissable for those in the following roles:

Associate Clinician, Biomarker Specialist, Brand Manager, Business Development Director, Chief Executive Officer, Chief Medical Officer, Chief Scientific Officer, Clinical Regulatory Strategy Manager, Clinical Pharmacologist, Clinical Trial Manager, Commercial Director, Director of Medical Affairs, Head Global Licensing Respiratory, Head of Clinical Science, Head of Discovery, Head of Global Data Informatics - Global Preclinical R&D, Head of In-Vitro Biology, Head of Pharmacology, Head of Respiratory Pharmacology, Managing Director, Medical Affairs Director, Medical Director, Principal Scientist, Vice President, VP Chemistry, VP Inflammatory Disease, VP, Clinical Research Immunology. VP, Research

Attendees at previous SMi COPD events include:

3M Healthcare, 4SC, Accovion, Actelion, Actimis, Activaero, Aeropharm, AstraZeneca, Bayer, Bedfont Scientific, Biomedical Systems Europe, Biotie Therapies, Boehringer Ingelheim, CareFusion, Centocor, Chiesi, Deepbreeze, Galapagos, Genentech, GSK, Grunenthal, Laboratorios Almirall, MedImmune, Merck, Mpex, Munidpharma, Napp, Novartis, Nycomed, Pfizer, Revotar, Roche, Sanofi-Aventis, Schering Plough, Sepracor, Synirgen, Topigen, UCB & Vitalograph.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial School Of Medicine London

9:10 Current overview of the COPD field

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial School Of Medicine London

  • Mechanisms of exacerbations of COPD
  • Novel treatment strategies
  • What does the future hold in terms of drug development
  • 9:50 Anti-inflammatory drugs in COPD

    Daniel Bock

    Daniel Bock, Chief Scientific Officer, Revotar Biopharmaceuticals

  • Rationale and unmet needs
  • Potential benefits: from prevention to restructuring
  • Challenges in drug development: how to translate into clinical benefit?
  • 10:25 Morning Coffee

    10:45 Immunology of COPD

  • Innate immune responses
  • Adaptive immune responses
  • Comparing and contrasting different responses
  • Loss of regulation
  • Matthew Catley

    Matthew Catley, Team Leader R and I, AstraZeneca

    11:25 RC-Kinase; a novel target implicated in COPD

    Kevin Bacon

    Kevin Bacon, Chief Scientific Officer, Axikin

    • Effects of small molecule inhibitors in mouse models of smoke-induced inflammation and fibrosis
    • Identification and characterization of a novel COPD-relevant kinase
    • Immune mechanisms
    • Generation of small molecule inhibitors and characterization in smoking, fibrosis and oncology models relevant to COPD and its co-morbidities

    12:00 Measuring neutrophil kinetics in COPD

    Edwin Chilvers

    Edwin Chilvers, Professor of Respiratory Medicine, University of Cambridge School of Clinical Medicine

  • Use or radiolabelled neutrophils to quantify lung inflammation
  • Kinetics and fate of circulating neutrophils in man
  • Early studies of intravascular kinetics and fate of human eosinophils
  • Opportunity to use radiolabelled inflammatory cells to perform proof of principle therapeutic trials
  • 12:35 Networking Lunch

    13:45 Effective management of COPD

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

  • What are the burdens to society, the patient and to the economy?
  • What is the root of these problems
  • Computer guided diagnosis and treatment algorithms
  • Lessons from Asthma that we can use in COPD
  • 14:25 Clinical trial design considerations

    Christine Tiesler

    Christine Tiesler, Associate Director, Late Stage Research, PPD Development GmbH & Co.KG

     

    • Understanding current clinical trial guidelines for COPD
    • Are exacerbations the most relevant outcome parameters in COPD clinical trials
    • Long term observations
    • Short term studies

    15:05 Afternoon Tea

    15:25 Novel strategies in exacerbation management

    William Macnee

    William Macnee, Professor of Respiratory and Environmental Medicine, University of Edinburgh

    • Exacerbation definitions
    • Impact of exacerbations
    • Exacerbation prevention
    • Treatment of exacerbations

    16:05 Computational modelling of the lung: towards understanding asthma and COPD

    Kelly Burrowes

    Kelly Burrowes, EPSRC Post-Doctoral Research Fellow, University Of Oxford

  • Developing patient-specific computational models;
  • Introduction to the AirPROM AND Synergy-COPD European projects
  • Developing multi-scale computational models
  • Application of the models to understanding airway disease
  • 16:40 Glucose homeostasis: a target for prevention and treatment of exacerbations

    Emma Baker

    Emma Baker, Professor of Clinical Pharmacology, St George's, University of London

     

  • Airway and systemic glucose homeostasis in health and disease
  • Abnormal glucose homeostasis and COPD exacerbations
  • Therapeutic approaches and clinical trials
  • 17:20 Chairman's Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Wisia Wedzicha

    Wisia Wedzicha, Professor of Respiratory Medicine, University College London

    9:10 Understanding COPD exacerbations

    Paola Casarosa

    Paola Casarosa, Global Head Business Development and Licensing Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG

  • Understanding exacerbation causes: clinical evidence for role of viruses, bacterias…
  • Pharmacological interventions which are effective for the reduction of exacerbation frequency and severity . Non-pharmacological therapies (such as pulmonary rehabilitation, and home ventilatory support)
  • The future of exacerbation prevention: what is in the pipeline?
  • 9:50 Managing exacerbations of COPD

    Wisia Wedzicha

    Wisia Wedzicha, Professor of Respiratory Medicine, University College London

  • Guidelines for COPD exacerbation prevention
  • Novel bronchodilator approaches for exacerbation prevention
  • Combination therapy with ICS and exacerbation prevention
  • Phosphodiesterase inhibitors eg roflumilast and other anti-inflammatory therapy
  • Can managing the acute exacerbation affect exacerbation frequency
  • 10:30 Morning Coffee

    11:00 Targeting exacerbations of COPD

    Emma Hickman

    Emma Hickman, Research Investigator, Novartis

  • Brief overview of exacerbations
  • Developing pre-clinical models of acute COPD exacerbations
  • Limitations of pre-clinical models
  • Looking to the future for treating exacerbations 
  • 11:40 COPD and Co-morbidities

    John Hurst

    John Hurst, Senior Clinical Lecturer, Honorary Consultant, University College London

  • An NHS viewpoint
  • What tools are currently available to us?
  • Exploring methods to prevent exacerbations in COPD
  • 12:20 Bronchiectasis in patients with COPD

    Nabil Jarad

    Nabil Jarad, Consultant Respiratory Physician, Bristol Royal Infirmary

  • An NHS viewpoint 
  • What tools are currently available to us?
  • Exploring methods to prevent exacerbations in COPD 
  • 13:00 Networking Lunch

    14:00 From molecule to medicine – obstacles on the way from discovery to market

  • Oral or inhaled? developability assessment of new compounds in the treatment of COPD
  • Physical properties and stability – a good drug doesn´t always make a good product
  • DPI, MDI or nebuliser? Selection criteria from the products point of view
  • Manufacturing challenges for inhaled drug products
  • The future of development and manufacturing of inhaled products
  • Frank Thielmann

    Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG

    14:35 Translational Biomarkers in Respiratory Diseases – What They Can Deliver

    Magnus Nord

    Magnus Nord, Director Safety Science, Associate Professor, AstraZeneca

  • Current developments in Safety Biomarkers - definitions and key principles
  • Obstacles in Safety Biomarker development, validation and clinical qualification
  • Imaging vs circulation biomarkers in clinical drug safety
  • Case studies of Safety Biomarker applications in COPD drug development and beyond
  • 15:10 Afternoon Tea

    15:40 Novel antagonists to prevent airway inflammation

    Louise Donnelly

    Louise Donnelly, Reader in Respiratory Cell Biology, National Heart and Lung Institute Imperial College

  • Developments in inflammation in airways disease
  • Choosing novel targets
  • Novel effective antagonists
  • Current trials of novel antagonists
  • 16:15 Combination therapies in COPD

    Geoff Down

    Geoff Down, Chief Medical Officer, Prosonix Ltd

  • Unmet needs in the management of COPD patients
  • Scientific rationale for combination therapies
  • Delivering inhaled combination therapy
  • Discussion into future developments in the field
  • 16:50 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Sebastian Johnston

    Sebastian Johnston

    Professor of Respiratory Medicine, Imperial School Of Medicine London

    Christine Tiesler

    Associate Director, Late Stage Research, PPD Development GmbH & Co.KG
    Christine Tiesler

    Daniel Bock

    Chief Scientific Officer, Revotar Biopharmaceuticals
    Daniel Bock

    Edwin Chilvers

    Professor of Respiratory Medicine, University of Cambridge School of Clinical Medicine
    Edwin Chilvers

    Emma Baker

    Professor of Clinical Pharmacology, St George's, University of London
    Emma Baker

    Emma Hickman

    Research Investigator, Novartis
    Emma Hickman

    Ewan Walters

    Medical Director, Teva UK Ltd
    Ewan Walters

    Frank Thielmann

    Operational Lead, Inhalation New Solids, Novartis Pharma AG
    Frank Thielmann

    Geoff Down

    Chief Medical Officer, Prosonix Ltd
    Geoff Down

    John Hurst

    Senior Clinical Lecturer, Honorary Consultant, University College London
    John Hurst

    Jonathan Pritchard

    Business Development Manager, Clinical Trials, Vitalograph
    Jonathan Pritchard

    Kelly Burrowes

    EPSRC Post-Doctoral Research Fellow, University Of Oxford
    Kelly Burrowes

    Kevin Bacon

    Chief Scientific Officer, Axikin
    Kevin Bacon

    Louise Donnelly

    Reader in Respiratory Cell Biology, National Heart and Lung Institute Imperial College
    Louise Donnelly

    Magnus Nord

    Director Safety Science, Associate Professor, AstraZeneca
    Magnus Nord

    Matthew Catley

    Team Leader R and I, AstraZeneca
    Matthew Catley

    Nabil Jarad

    Consultant Respiratory Physician, Bristol Royal Infirmary
    Nabil Jarad

    Paola Casarosa

    Global Head Business Development and Licensing Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG
    Paola Casarosa

    Sabine Häußermann

    Director Business Development, Inamed GmbH
    Sabine Häußermann

    Sebastian Johnston

    Professor of Respiratory Medicine, Imperial School Of Medicine London
    Sebastian Johnston

    William Macnee

    Professor of Respiratory and Environmental Medicine, University of Edinburgh
    William Macnee

    Wisia Wedzicha

    Professor of Respiratory Medicine, University College London
    Wisia Wedzicha

    Workshops

    Inhalation Device Development
    Workshop

    Inhalation Device Development

    Copthorne Tara Hotel
    24th October 2012
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.